BioDelivery Sciences to Report Third Quarter 2021 Financial Results on November 3, 2021
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) will report its third quarter 2021 financial results on November 3, 2021, before U.S. markets open. A conference call and webcast will follow at 8:30 AM ET to discuss the results and provide a business update. BDSI focuses on chronic conditions and uses its proprietary BioErodible MucoAdhesive (BEMA®) technology to develop therapies for serious issues like chronic pain and opioid-induced constipation. The announcement marks an important date for stakeholders looking for insights into the company's financial health.
- Focus on chronic condition treatments may lead to strong market demand.
- Utilization of proprietary BEMA® technology highlights innovation.
- None.
RALEIGH, N.C., Oct. 20, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, announced today that it will report its third quarter 2021 financial results before the open of the U.S. financial markets on Wednesday, November 3, 2021. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
Conference Call Dial-In & Webcast Information:
| Date: | Wednesday, November 3, 2021 |
| Time: | 8:30 AM Eastern Time |
| Domestic: | 877-407-0789 |
| International: | 201-689-8562 |
| Conference ID: | 13723637 |
| Webcast: | http://public.viavid.com/index.php?id=146730 |
ABOUT BIODELIVERY SCIENCES INTERNATIONAL, INC.
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation.
© 2021 BioDelivery Sciences International, Inc. All rights reserved.
Contact:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com
FAQ
When will BioDelivery Sciences report its Q3 2021 financial results?
What time is the conference call for BioDelivery Sciences Q3 results?
What is BioDelivery Sciences' focus area?
What technology does BioDelivery Sciences use in its products?
